dr. sartor on the significance of the reassure trial in mcrpc
Published 4 years ago • 67 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:30
dr. sartor on the vision trial in mcrpc
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
-
0:55
dr. sartor on patients in the alsympca radium-223 trial
-
1:24
dr. sartor on mechanism of action and safety of radium-223 in mcrpc
-
1:25
dr. sartor on progress for the treatment of prostate cancer
-
1:16
dr. sartor on the implications of the analysis of sipuleucel-t in prostate cancer
-
2:09
dr. sartor discusses sequencing therapies in prostate cancer
-
23:20
intermediate-risk prostate cancer treatment - musc hollings
-
4:21
dendreon provenge mechanism of action
-
7:42
how to treat men with advanced castration resistant prostate cancer with ar directed therapy
-
10:26
trt clinic vs trt service
-
1:25
dr. oliver sartor on the future of identifying phenotypic and genomic heterogeneity in mcrpc
-
0:53
dr. sartor on impact of radium-223 for community oncologists
-
0:51
dr. sartor on the next steps with sipuleucel-t for prostate cancer
-
0:42
oliver sartor, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
1:04
dr. sartor discusses custirsen as treatment for prostate cancer
-
1:25
dr. sartor discusses the novel agent radium-223
-
1:08
dr. sartor on provenge in combination with radium-223
-
1:08
dr. a. oliver sartor on the mechanism of action of radium-223
-
25:01
case study 1: hormone-sensitive, metastatic crpc
-
1:56
dr. sartor on promising treatment approaches in prostate cancer
-
17:29
prostate cancer: state-of-the-art diagnosis and non-invasive treatment